Fourth quarter and full year 2023 results
Fourth quarter and full year 2023 results were reviewed by management during a live audio webcast with the financial community on February 1st, 2024. The presentation was followed by a Q&A session.
14:30 - 16:00 CET (8:30am – 10am EST)
Featuring
![Paul Hudson](/optim/dotcom/content-app/events/quaterly-results/2023/2023-q4-2023-results/paul-hudson-featuring_20240126082723.jpg?size=small)
Paul Hudson
Chief Executive Officer
![Jean-Baptiste de Chatillon](/optim/dotcom/content-app/events/quaterly-results/2023/2023-q4-2023-results/jb-dechatillon-featuring_20240126082712.jpg?size=small)
Jean-Baptiste de Chatillon
Chief Financial Officer
![Brian Foard](/optim/dotcom/content-app/events/quaterly-results/2023/2023-q4-2023-results/brian-foard-featuring_20240126082756.jpg?size=small)
Brian Foard
Specialty Care
![Olivier Charmeil](/optim/dotcom/content-app/events/quaterly-results/2023/2023-q4-2023-results/olivier-charmeil-featuring_20240126082739.jpg?size=small)
Olivier Charmeil
General Medicines
![Houman Ashrafian](/optim/dotcom/content-app/events/quaterly-results/2023/2023-q4-2023-results/houman-ashrafian-featuring_20240126082806.jpg?size=small)
Houman Ashrafian
R&D
![Thomas Triomphe](/optim/dotcom/content-app/events/quaterly-results/2023/2023-q4-2023-results/thomas-triomphe-featuring_20240126082814.jpg?size=small)
Thomas Triomphe
Vaccines
![Julie van Ongevalle](/optim/dotcom/content-app/events/quaterly-results/2023/2023-q4-2023-results/julie-van-ongevall-featuring_20240126082731.jpg?size=small)
Julie van Ongevalle
Consumer Healthcare
![Roy Papatheodorou](/optim/dotcom/content-app/events/quaterly-results/2023/2023-q4-2023-results/roy-papatheodorou-featuring_20240126082746.jpg?size=small)
Roy Papatheodorou
General Counsel
Highlights
Paul Hudson comments on 2023 results
![](/optim/dotcom/content-app/events/quaterly-results/2023/2023-q4-2023-results/thumbnail-youtube-paul-hudson.jpg?size=large)
Full-Year 2023 results and R&D highlights
2023 was a turning-point year for Sanofi, paving the way for our scientific leadership in Immunology. Coupled with our AI at-scale ambitions, we go forward as a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth.
![Paul Hudson](/optim/dotcom/content-app/events/quaterly-results/2023/2023-q4-2023-results/bio-paul-hudson.jpg?size=small)
Paul Hudson
Chief Executive Officer